News from the United Kingdom’s Institute of Cancer Research (ICR) published in The Lancet Oncology reports that targeted radiation treatment is “greatly improving” the quality of life for cancer patients.
ICR writes:
Patients with advanced prostate cancer who were treated with the ‘search and destroy’ drug, called Lu-PSMA (177Lu-PSMA-617), alongside standard care, experienced a higher quality of life when than those treated with standard care alone.
…The researchers, led by The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust, and the Gustave Roussy, France, also found that patients treated with the drug lived for longer before their pain levels increased. Metastatic prostate cancer spreads to the bone in around nine in 10 patients and can cause severe pain.
